This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Ascendis Pharma Growth Disorders A/s. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Ana Bernhard - Innovator in Controlled-Release CNP Agonists
Introduction
Ana Bernhard is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled-release CNP agonists. Her innovative work focuses on enhancing the stability and efficacy of these compounds, which are crucial for various therapeutic applications.
Latest Patents
Ana Bernhard holds a patent for "Controlled-release CNP agonists with increased NEP stability." This invention relates to controlled-release CNP agonists that exhibit an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay compared to the corresponding released CNP agonist. The patent also covers pharmaceutical compositions comprising these controlled-release CNP agonists, their uses, and methods of treatment.
Career Highlights
Ana is currently associated with Ascendis Pharma Growth Disorders A/S, where she continues to advance her research and development efforts. Her work is instrumental in addressing growth disorders through innovative pharmaceutical solutions.
Collaborations
Ana collaborates with notable colleagues, including Kennett Sprogøe and Harald Rau. Their combined expertise contributes to the success of their projects and enhances the impact of their research in the pharmaceutical industry.
Conclusion
Ana Bernhard's contributions to the field of controlled-release CNP agonists exemplify her dedication to innovation in pharmaceuticals. Her work not only advances scientific knowledge but also holds the potential to improve treatment options for patients.